In this context, the ongoing Phase I ASSET trial (NCT05143229) seeks to establish the recommended Phase II dose of SG in conjunction with alpelisib for patients with metastatic or locally recurrent HER2-negative breast cancer, while also assessing the pharmacokinetics and ORR associated with this combination therapy. This evidence concerns the gene ERBB2 and breast carcinoma.